Voyager Therapeutics Inc. Common Stock
Financials
Valuation Metrics
Voyager Therapeutics Inc. Common Stock's Market Cap is $187M. At end of 2025 it was $231M. Ranked #3034 of 3,121 in US market (top 97%), #1394 of 1,463 on NASDAQ (top 95%), #255 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 96%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $187M | US#3,034/3,121 Sec#255/266 |
| Revenue | $34M | US#2,799/3,121 Sec#159/266 |
| Net Income | $-108M | US—/3,121 Sec—/266 |
| Total Assets | $198M | US#2,995/3,121 Sec#246/266 |
| Net Assets | $154M | US#2,743/3,121 Sec#204/266 |
| Employees | 141 | US#2,565/3,121 Sec#154/266 |
| Value | ||
| P/B | 1.21x | US#583/3,121 Sec#19/266 |
| P/S | 5.42x | US#2,345/3,121 Sec#76/266 |
| FCF Yield | -65.03% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -69.78% | US#2,752/3,121 Sec#185/266 |
| ROA | -54.48% | US#3,003/3,121 Sec#221/266 |
| Op. Margin | -340.08% | US#2,796/3,121 Sec#148/266 |
| Revenue Growth | -19.07% | US#2,686/3,121 Sec#153/266 |
| Financial Health | ||
| Debt Ratio | 28.10% | US#309/3,121 Sec#99/266 |
| Total Debt | $33M | US#2,687/3,121 Sec#173/266 |
| FCF | $-121M | US#2,677/3,121 Sec#160/266 |
| Cash | $36M | US#2,714/3,121 Sec#243/266 |
| Current Ratio | 7.51x | US#338/3,121 Sec#105/266 |
| Performance | ||
| 1Y Return | -31.18% | US#2,595/3,121 Sec#224/266 |
| 1M Return | -9.38% | US#2,179/3,121 Sec#164/266 |
| From 52W High | -44.32% | US#2,605/3,121 Sec#206/266 |
| 1Y MDD | -43.71% | US#2,201/3,121 Sec#158/266 |
| Trading | ||
| Volume | 467,408 shares | US#1,731/3,121 Sec#184/266 |
| Trading Value | $1M | US#2,898/3,121 Sec#247/266 |
| Per Share | ||
| EPS | $-1.78 | US—/3,121 Sec—/266 |
| BPS | $2.56 | US#2,533/3,121 Sec#168/266 |
Company Info
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.